Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy

Diabetes

Volumn 46, Issue 10, 1997, Pages 1557-1562

  Rachman, Jonathan ^a,b   Levy, Jonathan C ^a   Barrow, Beryl A ^a   Manley, Susan E ^a   Turner, Robert C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLICLAZIDE; INSULIN; INSULIN ZINC SUSPENSION; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIETARY INTAKE; DOSE RESPONSE; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030845937     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.46.10.1557     Document Type: Article

References (42)

1. Rastogi G, Sinha MK, Dash RJ: Insulin and proinsulin content of pancreases from diabetic and nondiabetic subjects. Diabetes 22:804-807, 1973
2. Horwitz D, Starr JL, Mako ME, Blackard WG, Rubenstein AH: Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 55:1278-1283, 1975
3. Bergenstal RM, Cohen RM, Lever E, Polonsky K, Jaspan J, Blix PM, Revers R, Olefsky JM, Kolterman O, Steiner K, Cherrington A, Frank B, Galloway J, Rubenstein AH: The metabolic effects of biosynthetic human proinsulin in individuals with type 1 diabetes. J Clin Endocrinol Metab 58:973-979, 1984
4. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30:698-702, 1987
5. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y: Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355-360, 1988
6. Shiraishi I, Iwamoto Y, Kuzuya T, Matsuda A, Kumakura S: Hyperinsulinaemia in obesity is not accompanied by an increase in serum proinsulin/insulin ratio in groups of human subjects with and without glucose intolerance. Diabetologia 34:737-741, 1991
7. Duckworth WC, Kitabchi AE, Heinemann M: Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 53:418-427, 1972
8. Gorden P, Hendricks CM, Roth J: Circulating proinsulin-like component in man: increased proportion in hypoinsulinaemic states. Diabetologia 10:469-474, 1974
9. Deacon CF, Schleser-Mohr S, Ballmann M, Willms B, Conlon JM, Creutzfeldt W: Preferential release of proinsulin relative to insulin in non-insulin-dependent diabetes mellitus. Acta Endocrinol 119:549-554, 1988
10. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN: Insulin deficiency in non-insulin-dependent diabetes. Lancet i:293-295, 1989
11. Williams DRR, Byrne C, Clark PMS, Cox L, Day NE, Rayman G, Wang T, Hales CN: Raised proinsulin concentration as early indicator of β-cell dysfunction. BMJ 303:95-96, 1991
12. Davies MJ, Rayman G, Gray IP, Day JL, Hales CN: Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose intolerance. Diabet Med 10:313-320, 1993
13. Temple RC, Clark PMS, Nagi DK, Schneider AE, Yudkin JS, Hales CN: Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol 32:689-693, 1990
14. Kahn SE, Halban PA: Recently released β-cell granule constituents as an indicator of proinsulin processing in NIDDM (Abstract). Diabetologia 38 (Suppl. 1):A114, 1995
15. Levy JC, Clark PM, Hales CN, Turner RC: Normal proinsulin responses to glucose in mild type II subjects with subnormal insulin response. Diabetes 42:162-169, 1993
16. Mako ME, Starr JI, Rubenstein AH: Circulating proinsulin in patients with maturity onset diabetes. Am J Med 63:865-869, 1977
17. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowalyk S, Bennett PH, Porte D: Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247-1253, 1990
18. Roder ME, Dinesen B, Houssa P, Hartling SG, Sodoyez-Goffaux F, Binder C: Elevated intact proinsulin in NIDDM is not due to obesity (Abstract). Diabetologia 38 (Suppl. 1):A114, 1995
19. Ward WK, Wallum BJ, Beard JC, Taborsky GJ, Porte D: Reduction of glycemic potentiation: sensitive indicator of β-cell loss in partially pancreatectomized dogs. Diabetes 37:723-729, 1988
20. Porte D, Kahn SE: Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 38:1333-1336, 1989
21. Kahn SE, Beard JC, Schwartz MW, Ward WK, Lun Ding H, Bergman RN, Taborsky GJ, Porte D: Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562-568, 1989
22. Kahn SE, Horber FF, Prigeon RL, Haymond MW, Porte D: Effect of glucocorticoid and growth hormone treatment on proinsulin levels in humans. Diabetes 42:1082-1085, 1993
23. Heaton DA, Millward BA, Gray IP, Tun Y, Hales CN, Pyke DA, Leslie RDG: Increased proinsulin levels as an early indicator of β-cell dysfunction in non-diabetic twins of type 1 (insulin-dependent) diabetic patients. Diabetologia 31:182-184, 1988
24. Hartling SG, Lindgren F, Dahlqvist G, Persson B, Binder C: Elevated proinsulin in healthy siblings of IDDM patients independent of HLA identity. Diabetes 38:1271-1274, 1989
25. Spinas GA, Snorgaard O, Hartling SG, Oberholzer M, Berger W: Elevated proinsulin levels related to islet cell antibodies in first-degree relatives of IDDM patients. Diabetes Care 15:632-637, 1992
26. U.K. Prospective Study of Therapies of Maturity-Onset Diabetes: Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 24:404-411, 1983
27. Matthews DR, Hosker JP: Unbiased and flexible iterative computer program to achieve glucose clamping. Diabetes Care 12:156-159, 1989
28. U.K. Prospective Diabetes Study (UKPDS) XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534-544, 1994
29. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME: Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39:578-582, 1993
30. Kjems LL, Roder ME, Dinesen B, Hartling SG, Jorgensen PN, Binder C: Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies. Clin Chem 39:2146-2150, 1993
31. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP: Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Diabet Med 11:293-298, 1994
32. Prigeon RL, Jacobson RK, Porte D, Kahn SE: Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:3295-3298, 1996
33. Mohammed-Ali V, Panahloo A, Denver E, Andres C, Yudkin JS: Sulphonylurea therapy stimulates basal and post glucose load levels of proinsulin (Abstract). Diabetologia 38 (Suppl. 1):A115, 1995
34. Madsbad S, Hartling SG, Faber OK: C-peptide and proinsulin. In International Textbook of Diabetes Mellitus. Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, Eds. Chichester, Wiley, 1992, p. 303-332
35. Cohen RM, Nathan DM, Clements RS: Hyperproinsulinemia in type II diabetes. Diabetes Care 15:723-724, 1992
36. Polonsky KS, Gumbiner B, Ostrega D, Griver K, Tager H, Henry RR: Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM. Diabetes 43:871-877, 1994
37. Yoshioka N, Kuzuya T, Matsuda A, Iwamoto Y: Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes 38:262-266, 1989
38. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP: Improved beta cell function, with reduction in secretion of intact and 32/33 split proinsulin, after dietary intervention in subjects with type 2 diabetes mellitus. Diabet Med 11:71-78, 1994
39. Rhodes CJ, Alarcon C: What β-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism. Diabetes 43:511-517, 1994
40. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY: Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 44:173-179, 1995
41. Mykkanen L, Haffner SM, Kuusisto J, Pyorala K, Hales CN, Laakso M: Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects. Diabetologia 38:1176-1182, 1995
42. Nijpels G, Popp-Snijders C, Kostense PJ, Bouter LM, Heine RJ: Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn Study. Diabetologia 39:113-118, 1996